|
|
||||||||||
|
J Am Coll Cardiol, 2002; 40:491-498 © 2002 by the American College of Cardiology Foundation |




* Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, Göteborg, Sweden
Department of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden
Henry Ford Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan, USA
Section of Cardiology, Rikshospitalet, Oslo, Norway
|| Nordic School of Public Health, Göteborg, Sweden
Manuscript received December 28, 2001; revised manuscript received April 8, 2002, accepted April 30, 2002.
* Reprint requests and correspondence: Dr. John Wikstrand, Wallenberg Laboratory, Sahlgrenska University Hospital, SE 413 45 Göteborg, Sweden.
john.wikstrand{at}wlab.gu.se
OBJECTIVES: We performed a post-hoc subgroup analysis in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) with the aim of reporting on the heart rate (HR) response during the titration phase and clinical outcomes from the three-month follow-up visit to end of study in two dosage subgroups: one that had reached more than 100 mg of metoprolol CR/XL once daily (high-dose group; n = 1,202; mean 192 mg) and one that had reached 100 mg or less (low-dose group; n = 412; mean 76 mg).
BACKGROUND: Clinicians have questioned whether patients need to reach the target beta-blocker dose to receive benefit.
METHODS: Outcome (Cox-adjusted) was compared with all placebo patients with dose available at the three-month visit (n = 1,845).
RESULTS: Data indicated somewhat higher risk in the low-dose group compared with the high-dose group. Heart rate was reduced to a similar degree in the two dose groups, indicating higher sensitivity for beta-blockade in the low-dose group. The reduction in total mortality with metoprolol CR/XL compared with placebo was similar: 38% (95% confidence interval [CI], 16 to 55) in high-dose group (p = 0.0022) and also 38% (95% CI, 11 to 57) in the low-dose group (p = 0.010).
CONCLUSIONS: Risk reduction was similar in the high- and low-dose subgroups, which, at least partly, may be the result of similar beta-blockade as judged from the HR response. The results support the idea of an individualized dose-titration regimen, which is guided by patient tolerability and the HR response. Further research is needed to shed light on why some patients respond with a marked HR reduction and reduced mortality risk on a relatively small dose of a beta-blocker.
| ||||||||||||||||||
This article has been cited by other articles:
![]() |
C. Funck-Brentano Beta-blockade in CHF: from contraindication to indication Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C19 - C27. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Follath Beta-blockade today: the gap between evidence and practice Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C28 - C34. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Willenheimer How to begin treatment in chronic heart failure? Results of CIBIS III Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C43 - C50. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lechat and R. Willenheimer Discussion summary: key clinical questions Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C58 - C60. [Full Text] [PDF] |
||||
![]() |
J. M. Aranda Jr, G. W. Woo, R. S. Schofield, E. M. Handberg, J. A. Hill, A. B. Curtis, S. F. Sears, J. S. Goff, D. F. Pauly, and J. B. Conti Management of Heart Failure After Cardiac Resynchronization Therapy: Integrating Advanced Heart Failure Treatment With Optimal Device Function J. Am. Coll. Cardiol., December 20, 2005; 46(12): 2193 - 2198. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Lenzen, E. Boersma, W. J.M. Scholte op Reimer, A. H.M.M. Balk, M. Komajda, K. Swedberg, F. Follath, M. Jimenez-Navarro, M. L. Simoons, and J. G.F. Cleland Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure Eur. Heart J., December 2, 2005; 26(24): 2706 - 2713. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Metra, C. Torp-Pedersen, K. Swedberg, J. G.F. Cleland, A. Di Lenarda, M. Komajda, W. J. Remme, B. Lutiger, A. Scherhag, M. A. Lukas, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial Eur. Heart J., November 1, 2005; 26(21): 2259 - 2268. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Willenheimer, D. J. van Veldhuisen, B. Silke, E. Erdmann, F. Follath, H. Krum, P. Ponikowski, A. Skene, L. van de Ven, P. Verkenne, et al. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III Circulation, October 18, 2005; 112(16): 2426 - 2435. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F. McBride and C. M. White Critical Differences Among Beta-Adrenoreceptor Antagonists in Myocardial Failure: Debating the MERIT of COMET J. Clin. Pharmacol., January 1, 2005; 45(1): 6 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J Tangeman and J H. Patterson Extended-Release Metoprolol Succinate in Chronic Heart Failure Ann. Pharmacother., May 1, 2003; 37(5): 701 - 710. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gheorghiade, W. S. Colucci, and K. Swedberg {beta}-Blockers in Chronic Heart Failure Circulation, April 1, 2003; 107(12): 1570 - 1575. [Full Text] [PDF] |
||||
![]() |
T. Simon, M. Mary-Krause, C. Funck-Brentano, Ph. Lechat, P. Jaillon, and on behalf of CIBIS II investigators Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II) Eur. Heart J., March 2, 2003; 24(6): 552 - 559. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |